

CITATION REPORT

List of articles citing

Management of Antiviral Resistance in Patients with Chronic Hepatitis B

DOI: 10.1177/135965350400900522
Antiviral Therapy, 2004, 9, 679-693.

Source: <https://exaly.com/paper-pdf/145594042/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
158	Entecavir for the treatment of chronic hepatitis B. 2004 , 2, 853-71		39
157	Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. 2005 , 34 Suppl 1, S34-43		31
156	Management of patients co-infected with hepatitis B virus and HIV. 2005 , 5, 374-82		57
155	Complications in treating chronic hepatitis B in patients with HIV. 2005 , 6, 2831-42		1
154	[New virologic tests and their application in management of chronic hepatitis B]. 2006 , 35, 317-26		1
153	Management of drug-resistant chronic hepatitis B. 2006 , 10, 275-302, viii		10
152	[Treatment of viral hepatitis (I). Treatment of chronic hepatitis B]. 2006 , 24, 453-61; quiz 462		5
151	[Hepatitis B and C virus antiviral resistance]. 2006 , 24, 576-84		0
150	Tratamiento de la resistencia al VHB. 2006 , 29, 59-64		2
149	Virology of hepatitis B and C viruses and antiviral targets. <i>Journal of Hepatology</i> , 2006 , 44, S10-3	13.4	23
148	HBV virological assessment. <i>Journal of Hepatology</i> , 2006 , 44, S71-6	13.4	29
147	Assessment of treatment efficacy in HBV infection and disease. <i>Journal of Hepatology</i> , 2006 , 44, S95-9	13.4	20
146	HBV drug resistance: mechanisms, detection and interpretation. <i>Journal of Hepatology</i> , 2006 , 44, 593-606	13.4	397
145	Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure. 2006 , 1, 361-376		3
144	Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. 2006 , 5, 1		25
143	A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 278-88	3.4	58
142	Antiviral drug resistance. 2006 , 71, 117-21		80

141	Définitions de la résistance aux antiviraux analogues dans le traitement de l'hépatite chronique B. 2006 , 30, 9-11		2
140	Conséquences cliniques de la résistance aux analogues antiviraux utilisés dans le traitement de l'hépatite chronique B. 2006 , 30, 12-16		
139	Prise en charge de la résistance aux analogues antiviraux chez un patient atteint d'hépatite chronique B compensée. 2006 , 30, 17-19		
138	Prise en charge de la résistance aux analogues antiviraux chez un patient atteint de cirrhose décompensée. 2006 , 30, 20-21		1
137	Evolution of multi-drug resistant hepatitis B virus during sequential therapy. <i>Hepatology</i> , 2006 , 44, 703-712	12.2	210
136	Hepatitis B in liver transplant recipients. 2006 , 12, S54-64		18
135	Hepatitis B virus mutations associated with antiviral therapy. <i>Journal of Medical Virology</i> , 2006 , 78 Suppl 1, S52-5	19.7	75
134	Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals. 2006 , 1, 197-209		2
133	Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. <i>Journal of General Virology</i> , 2007 , 88, 1133-1143	4.9	49
132	Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 341-9	5.1	20
131	Hepatitis B in the HIV-coinfected patient. 2007 , 45 Suppl 2, S57-65; discussion S66-7		33
130	Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. <i>Journal of Hepatology</i> , 2007 , 46, 791-6	13.4	29
129	Improving outcomes for patients with chronic hepatitis B. 2007 , 37, S67-78		4
128	Antiviral therapy of chronic hepatitis B: prevention of drug resistance. 2007 , 11, 869-92, ix		32
127	Clinical management of patients with recurrent viral hepatitis after liver transplantation. 2007 , 10, 46-52		1
126	Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. 2007 , 132, 543-50		57
125	Prophylaxis and treatment of hepatitis B in immunocompromised patients. 2007 , 39, 397-408		172
124	Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. 2007 , 39, 857-63		7

123	[Advances in the treatment of hepatitis B]. 2007 , 40, 451-62		9
122	Why do we not yet have combination chemotherapy for chronic hepatitis B?. 2007 , 186, 204-6		10
121	Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?. <i>Hepatology</i> , 2007 , 45, 266-8	11.2	25
120	Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. <i>Hepatology</i> , 2007 , 46, 254-65	11.2	377
119	Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. <i>Hepatology</i> , 2008 , 47, 447-54	11.2	140
118	Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. <i>Journal of Medical Virology</i> , 2007 , 79, 1664-70	19.7	22
117	Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 1220-5	4	5
116	The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 751-66	3.4	16
115	Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?. <i>Journal of Viral Hepatitis</i> , 2007 , 14 Suppl 1, 29-36	3.4	48
114	Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26 Suppl 2, 171-82	6.1	13
113	Improving outcomes for patients with chronic hepatitis B. 2007 , 9, 14-22		14
112	New developments in HBV molecular diagnostics and quantitative serology. <i>Hepatology International</i> , 2008 , 2, 3-11	8.8	16
111	The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. <i>Hepatology</i> , 2008 , 48, 88-98	11.2	429
110	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. 2008 , 26, 335-41		321
109	Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. <i>Liver International</i> , 2008 , 28, 699-704	7.9	4
108	Economic evaluation of chronic hepatitis B treatments in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 571-9	4	12
107	[Treatment of chronic hepatitis B]. 2008 , 32, 749-68		7
106	Chronic hepatitis B: preventing, detecting, and managing viral resistance. 2008 , 6, 268-74		58

105	Entecavir: a step forward in combating hepatitis B disease. 2008 , 9, 3095-109		6
104	Treatment of chronic hepatitis B and the implications of viral resistance to therapy. 2008 , 6, 191-9		7
103	Hepatitis B: reflections on the current approach to antiviral therapy. <i>Journal of Hepatology</i> , 2008 , 48 Suppl 1, S2-19	13.4	123
102	Introduction. 2008 , 2, 1-2		
101	[Hepatitis B in patients with HIV infection]. 2008 , 26 Suppl 7, 71-9		4
100	Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. 2008 , 134, 405-15		189
99	Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. 2008 , 8, 167-78		162
98	Current status of antiviral therapy for hepatitis B. 2008 , 1, 61-75		21
97	Resistance issues in treating chronic hepatitis B. 2008 , 3, 525-38		18
96	Chronic hepatitis B--new goals, new treatment. 2008 , 359, 2488-91		92
95	Telbivudine in the treatment of chronic hepatitis B. 2008 , 2, 13-22		4
94	Hepatitis B virus infection in the dialysis population: current perspectives. 2008 , 31, 386-94		13
93	Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 2544-50	9.7	18
92	Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. 2009 , 31, 360-6		11
91	Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. 2009 , 81, 147-55		49
90	Complex dynamics of hepatitis B virus resistance to adefovir. <i>Hepatology</i> , 2009 , 49, 50-9	11.2	25
89	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009 , 49, S174-84	11.2	166
88	Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. <i>Hepatology</i> , 2009 , 50, 743-51	11.2	27

87	Hepatitis B. 2009 , 4, 43-55		
86	Hepatitis B: Management of suboptimal response to oral antiviral therapy. <i>Current Hepatitis Reports</i> , 2009 , 8, 173-180		
85	A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 279-85	3.4	17
84	Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 149-55	3.4	46
83	Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. 2009 , 45, 114-8		40
82	Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2009 , 51, 11-20	13.4	168
81	2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. 2009 , 136, 486-95		470
80	Hepatitis B virus resistance to nucleos(t)ide analogues. 2009 , 137, 1593-608.e1-2		555
79	Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. <i>Antiviral Therapy</i> , 2009 , 14, 985-93	1.6	21
78	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. <i>Antiviral Therapy</i> , 2010 , 15, 13-22	1.6	5
77	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. <i>Antiviral Therapy</i> , 2010 , 15, 801	1.6	
76	[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. 2010 , 122, 280-302		2
75	Viral resistance in hepatitis B: prevalence and management. 2010 , 12, 62-9		6
74	Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. 2010 , 38, 58-61		45
73	Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. 2010 , 85, 512-9		73
72	Clevudine, to Treat Hepatitis B Viral Infection. 2010 , 383-408		
71	Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. 2010 , 11, 2243-9		7
70	Drug resistance in antiviral therapy. 2010 , 14, 439-59		22

69	Management of end-stage liver disease in chronic hepatitis B. 2010 , 14, 477-93		3
68	Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. 2011 , 9, 274-6		133
67	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011 , 55, 522-528	13.4	30
66	Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e432-8	3.4	17
65	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. <i>Liver International</i> , 2011 , 31, 676-84	7.9	39
64	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. 2011 , 92, 90-5		22
63	Current Management of HBV Antiviral Drug Resistance. <i>Current Hepatitis Reports</i> , 2011 , 10, 120-127		
62	Infections and the liver. 2011 , 29, 184-90		2
61	High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. <i>The Korean Journal of Hepatology</i> , 2012 , 18, 75-83		13
60	Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir. <i>Antiviral Therapy</i> , 2013 , 18, 77-85	1.6	9
59	Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. <i>Antiviral Therapy</i> , 2012 , 17, 1255-62	1.6	15
58	Management of treatment failure in chronic hepatitis B. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S112-22	3.4	98
57	Prevention and management of drug resistant hepatitis B virus infections. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 1432-40	4	11
56	Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. <i>BMC Gastroenterology</i> , 2012 , 12, 178	3	5
55	Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012 , 11, 55-64		1
54	Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. <i>Journal of Medical Virology</i> , 2012 , 84, 207-16	19.7	18
53	Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. <i>Liver International</i> , 2013 , 33 Suppl 1, 116-24	7.9	54
52	Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. <i>Liver International</i> , 2013 , 33 Suppl 1, 137-50	7.9	35

51	Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 445-52	3.4	34
50	Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2893-900	9.7	11
49	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2332-8	5.1	16
48	Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 710-9	6.1	17
47	A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. <i>BMC Infectious Diseases</i> , 2014 , 14, 608	4	13
46	Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 568-75	4	14
45	A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O90-O100	9.5	25
44	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. <i>Hepatology</i> , 2014 , 59, 1283-92	11.2	62
43	Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3209-15	9.7	9
42	Entecavir 1mg versus combined lamivudine/adefovur dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. <i>Arab Journal of Gastroenterology</i> , 2014 , 15, 1-5	1.7	3
41	On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. <i>Antiviral Therapy</i> , 2015 , 20, 369-75	1.6	46
40	A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response. <i>Infection, Genetics and Evolution</i> , 2015 , 33, 269-76	4.5	3
39	Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2841-6	1.9	11
38	Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients. <i>Journal of General Virology</i> , 2015 , 96, 663-670	4.9	10
37	Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents. <i>European Journal of Medicinal Chemistry</i> , 2015 , 90, 428-35	6.8	26
36	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 308-13	3.2	8
35	Hepatitis B Virus. 2016 , 713-770		
34	Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naïve elderly patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 193-8	2.2	3

33	Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. <i>Journal of Digestive Diseases</i> , 2016 , 17, 325-33	3.3	2
32	Activating the innate immune response to counter chronic hepatitis B virus infection. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1517-1527	5.4	6
31	Antiviral drug resistance as an adaptive process. <i>Virus Evolution</i> , 2016 , 2, vew014	3.7	107
30	Assessment of Adherence to Prescribed Therapy in Patients with Chronic Hepatitis B. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 53-64	6.2	3
29	Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 590-596	2.4	2
28	Clinical Virology: Diagnosis and Virologic Monitoring. <i>Molecular and Translational Medicine</i> , 2016 , 205-216.4		
27	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016 , 10, 1-98	8.8	1288
26	Linear antimicrobial peptides with activity against herpes simplex virus 1 and Aichi virus. <i>Biopolymers</i> , 2017 , 108, e22871	2.2	21
25	Involvement of PUF60 in Transcriptional and Post-transcriptional Regulation of Hepatitis B Virus Pregenomic RNA Expression. <i>Scientific Reports</i> , 2017 , 7, 12874	4.9	14
24	Research Methods and Techniques for Acute Exacerbation of Chronic Hepatitis B. 2019 , 49-118		
23	metabolism and pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: focus on interspecies comparison. <i>Xenobiotica</i> , 2020 , 50, 468-478	2	3
22	Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity. <i>Analytical Biochemistry</i> , 2020 , 597, 113642	3.1	2
21	Multicenter Evaluation of the Cepheid Xpert HBV Viral Load Test. <i>Diagnostics</i> , 2021 , 11,	3.8	3
20	Hepatitis Virus Resistance. 2008 , 291-323		1
19	The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns, and Mechanisms. 2009 , 519-530		1
18	Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. <i>Journal of General Virology</i> , 2006 , 87, 861-871	4.9	37
17	[Hepatitis B virus genetic diversity and mutant]. <i>The Korean Journal of Hepatology</i> , 2008 , 14, 446-64		9
16	[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. <i>The Korean Journal of Hepatology</i> , 2008 , 14, 503-12		3

15	[Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea]. <i>The Korean Journal of Hepatology</i> , 2009 , 15, 25-41		3
14	[Genotypic resistance to entecavir in chronic hepatitis B patients]. <i>The Korean Journal of Hepatology</i> , 2010 , 16, 147-57		2
13	DNA-guided hepatitis B treatment: viral load is insufficient with few exceptions. <i>World Journal of Gastroenterology</i> , 2009 , 15, 1530-1	5.6	1
12	Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6715-21	5.6	35
11	Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17100-6	5.6	2
10	Hepatitis B Virus. 2009 , 673-707		1
9	Management of Antiviral Resistance in Chronic Hepatitis B. 2009 , 273-287		
8	Monitoring of therapy in patients with chronic hepatitis B virus. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 736-40	2.2	2
7	The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns and Mechanisms. 2017 , 565-577		1
6	Spatial distribution of hepatitis B sero-antibodies among subjects in some Niger Delta communities: A public health risk. <i>International Journal of Family & Community Medicine</i> , 2018 , 2,	0.2	
5	Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV. <i>Antiviral Therapy</i> , 2005 , 10, 625-633	1.6	109
4	Major Causes of Antiviral drug Resistance and Implications for Treatment of Hepatitis B virus Monoinfection and Coinfection with HIV. <i>Antiviral Therapy</i> , 2007 , 12, 15-23	1.6	50
3	NICE Guidelines and a Treatment Algorithm for the Management of Chronic Hepatitis B: A Review of 12 Years Experience in West London. <i>Antiviral Therapy</i> , 2008 , 13, 1067-1076	1.6	4
2	Novel Approaches to New Therapies for Hepatitis B Virus Infection. <i>Antiviral Therapy</i> , 2006 , 11, 1-15	1.6	5
1	Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 669-680	1.6	85